Navigation Links
Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Date:8/19/2007

CRANBURY, N.J., Aug. 7 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD), a biopharmaceutical company developing small molecule, orally- delivered pharmacological chaperones for the treatment of human genetic diseases, today announced financial results for the second quarter of 2007. On a reported basis, calculated in accordance with U.S. generally accepted accounting principals (GAAP), Amicus announced a net loss attributable to common stockholders per share of $1.37 for the three months ended June 30, 2007. On a non-GAAP basis, Amicus reported a net loss attributable to common stockholders per share of $1.17 for the three months ended June 30, 2007. As of June 30, 2007, cash, cash equivalents, and marketable securities totaled $125.7 million.

"We continue to remain very confident in the potential for pharmacological chaperones to treat a range of human genetic diseases, beginning with the lysosomal storage disorders," stated John F. Crowley, President and CEO of Amicus Therapeutics. "We expect to deliver on three significant clinical milestones by the end of 2007: Phase II data for Amigal(TM) for Fabry disease; preliminary Phase II data in the 4-week Plicera(TM) switching study; and, complete Phase I data for AT2220 for Pompe disease."

Quarterly Highlights:

-- Amicus completed its IPO and sold a total of 5,000,000 shares of its

common stock at a public offering price of $15.00 per share. Gross

proceeds to Amicus totaled $75.0 million and after underwriting

discounts and commissions and offering expenses, net proceeds totaled

$68.1 million.

Financial Results

On a reported basis, the net loss attributable to common stockholders for the three
'/>"/>

SOURCE Amicus Therapeutics

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Amicus Therapeutics Presents Positive Results From Phase 1 Clinical Studies of Plicera for Gaucher Disease
2. Amicus Therapeutics Presents Preclinical Data from Studies of Plicera for Gaucher Disease
3. Amicus Therapeutics Presents Data From Preclinical and Phase 1 Studies of Amigal for Fabry Disease
4. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
5. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
6. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
7. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
8. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
9. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
10. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
11. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... 1, 2014  ResMed (NYSE: RMD ), a ... company to design complete sleep apnea solutions specifically for women, ... importance of a good night,s sleep. The ... that feeling tired is just part of living a busy ... a critical pillar of health, essential to not only living ...
(Date:10/1/2014)... 1, 2014 Trovagene, Inc., (NASDAQ:  TROV) ... that Eli Diamond , MD, Assistant Attending ... presented clinical data from an ongoing study demonstrating ... for the determination of oncogene mutational status in ... results were presented to both treating physicians and ...
(Date:10/1/2014)... 2014  Express Scripts (NASDAQ: ESRX ) ... Scripts Medicare ® Prescription Drug Plans (PDP) will ... WAG ) (NASDAQ: WAG ), ... support  for their Medicare dollars. Medicare beneficiaries ... or Choice plans for 2015 can ...
Breaking Medicine Technology:ResMed Launches Initiative to Help Women Get Better Sleep 2ResMed Launches Initiative to Help Women Get Better Sleep 3Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 2Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 3Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 4Express Scripts Collaborates with Walgreens to Create Value-Driven Medicare Prescription Drug Plan Pharmacy Network 2Express Scripts Collaborates with Walgreens to Create Value-Driven Medicare Prescription Drug Plan Pharmacy Network 3Express Scripts Collaborates with Walgreens to Create Value-Driven Medicare Prescription Drug Plan Pharmacy Network 4
... NEW YORK, Feb. 6, 2012 ... market research report is available ... Commercializing Angiogenesis Affecting ... Route to Consider Your Options ...
... Reportlinker.com announces that a new market research ... , World Market for Anti-Infectives (Antifungals, ... http://www.reportlinker.com/p0769020/World-Market-for-Anti-Infectives-Antifungals-Antibacterials-and-Antivirals- .html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication ... World Market for Anti-Infectives - focuses ...
Cached Medicine Technology:Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others 2Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others 3Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others 4Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others 5Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others 6Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others 7Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others 8Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others 9Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others 10Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others 11Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others 12Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others 13Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others 14Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others 15Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others 16Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others 17Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others 18Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others 19World Market for Anti-Infectives (Antifungals, Antibacterials and Antivirals) 2World Market for Anti-Infectives (Antifungals, Antibacterials and Antivirals) 3World Market for Anti-Infectives (Antifungals, Antibacterials and Antivirals) 4World Market for Anti-Infectives (Antifungals, Antibacterials and Antivirals) 5World Market for Anti-Infectives (Antifungals, Antibacterials and Antivirals) 6World Market for Anti-Infectives (Antifungals, Antibacterials and Antivirals) 7World Market for Anti-Infectives (Antifungals, Antibacterials and Antivirals) 8World Market for Anti-Infectives (Antifungals, Antibacterials and Antivirals) 9
(Date:10/1/2014)... research suggests the adage that encourages people to keep ... when it comes to exercise. When walking, staying focused ... to it appear shorter and help people walk there ... this technique to walking while looking around the environment ... of exercise. , "People are less interested in exercise ...
(Date:10/1/2014)... Insuranceragents.info has released a new blog ... plan for vulnerable family members. , Life insurance plans ... in the family should always carry a life insurance ... the rest of the family. , Clients can ... more from temporary coverage or from a permanent policy. ...
(Date:10/1/2014)... First Warning Systems, a pioneer in ... throughout the body, announced the company is changing its ... company’s breadth of upcoming product releases. The initial focus ... , “Our initial focus will be an ‘Internet of ... circadian cellular changes over time,” said Rob Royea, president ...
(Date:10/1/2014)... Farmington Company today announced it ... and visual identity helping brokers, consultants and companies ... to create greater benefit communication synergies. They unveiled ... empowering customers to better leverage Farmington Company’s industry-tested ... of the rebrand is the refreshed tagline: For ...
(Date:10/1/2014)... California (PRWEB) October 01, 2014 Beverly ... Dr. Kathleen Mojas is celebrating 20 years of private ... assisted hundreds of people to achieve greater joy and ... important list of warning signs and suggestions for anyone ... Dr. Mojas explains: “Believe it or not, it’s ...
Breaking Medicine News(10 mins):Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 3Health News:Life Insurance for Families - Clients Can Compare Affordable Rates Online! 2Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 2Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 3Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 4Health News:Farmington Company Launches Rebrand and New Positioning 2Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 2Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 3
... patients with cirrhosis have significant functional disability, require twice ... on the health care system, according to U-M research ... increase in obesity and aging of those with hepatitis ... climb among older Americans.. Cirrhosis is a ...
... TUESDAY, Jan. 10 (HealthDay News) -- Asian-Americans are more ... attack than whites, new research reveals, although this disparity ... quality improvement program. In the study, doctors examined ... patient was prescribed aspirin or ACE inhibitors (heart drugs) ...
... shows that older Americans with cirrhosis have significantly worse ... without this potentially deadly disease. In fact, findings now ... the American Association for the Study of Liver Diseases, ... amount of informal caregiving and contribute added strain on ...
... HealthDay Reporter , TUESDAY, Jan. 10 (HealthDay ... early clinical trial of the drug Nexavar (sorafenib) in ... in better news, an experimental drug known as ganetespib ... The results of both studies were to be presented ...
... 10, 2012. Kessler Foundation and the University of ... collaborate on clinical research projects applying virtual reality ... goal, according to USC,s Albert Rizzo, PhD of ... to conduct research to develop the evidence base ...
... Reporter , MONDAY, Jan. 9 (HealthDay News) -- For years, people ... of dying from a heart attack, stroke or cancer even if ... into question. Low-dose daily aspirin therapy does not reduce ... new study in the Jan. 9 online edition of the ...
Cached Medicine News:Health News:High rates of disability and health care use found in older Americans with cirrhosis 2Health News:Asian-Americans More Apt to Die in Hospital After Heart Attacks 2Health News:High rates of disability and health care use for older americans with cirrhosis 2Health News:Mixed News on Tough-to-Treat Lung Cancer 2Health News:Mixed News on Tough-to-Treat Lung Cancer 3Health News:Kessler Foundation and USC collaborate on clinical virtual reality for disability research 2Health News:Low-Dose Aspirin to Prevent First Heart Attack or Stroke? Not So Fast 2Health News:Low-Dose Aspirin to Prevent First Heart Attack or Stroke? Not So Fast 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: